Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-08T15:47:39.620Z Has data issue: false hasContentIssue false
  • English
  • Français

Association between metabolic syndrome, cognitive dysfunctions, and peripheral inflammation in schizophrenia

Published online by Cambridge University Press:  27 August 2024

A. Kancsev ,
O. Kelemen  and
S. Kéri
A. Kancsev*
Affiliation:
1Department of Psychiatry and Psychotherapy, SZSZBMK Jósa András University Teaching Hospital, Nyíregyháza
O. Kelemen
Affiliation:
2Department of Behavioral Sciences, Albert Szent-Györgyi Medical School, University of Szeged, Szeged 3Department of Psychiatry, Bács-Kiskun County Hospital, Kecskemét
S. Kéri
Affiliation:
4Department of Cognitive Science, Budapest University of Technology and Economics 5National Institute of Mental Health, Neurology, and Neurosurgery, Budapest 6Department of Physiology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Metabolic syndrome (MetS) is of primary clinical interest because of its harmful impact on the general health and quality of life of patients with psychotic disorders. Paradoxically, MetS is associated with impaired cognitive functions in patients receiving antipsychotics primarily shown to improve cognition (e.g., clozapine and olanzapine).

Objectives

In this study, we aimed to investigate the relationship between MetS, cognitive functions, and peripheral inflammation.

Methods

The participants were 154 patients with schizophrenia. Fifty-seven patients met the criteria of MetS. We evaluated cognitive functions with the Repeated Battery for the Assessment of Neuropsychological Status (RBANS). The Positive and Negative Syndrome Scale (PANSS) quantified the clinical symptoms. We also measured the plasma levels of IL-6 and C-reactive protein (CRP). In addition to conventional statistics, we also calculated Cohen’s effect size (d) and Bayes Factors (BF10).

Results

Results revealed that patients with MetS exhibited worse cognitive function relative to patients without Mets in attention (d = 0.19, BF10 = 2.3) and delayed memory (d = 0.25, BF10 = 5.7). No significant between-group differences existed in immediate memory, visuospatial functions, and language. The MetS and non-MetS groups did not differ in positive, negative, or general symptoms. Higher IL-6 levels were associated with worse delayed memory (r=-0.56, BF10=34.6).

Conclusions

Our results suggest that MetS-associated cognitive dysfunctions are less severe than reported in the literature: it was confined to two cognitive domains, the effect size was small, and the Bayesian evidence level was weak. Peripheral inflammation may mediate the association between MetS and long-term memory dysfunctions.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 67 , Special Issue S1: Abstracts of the 32nd European Congress of Psychiatry , April 2024 , pp. S241 - S242
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.